![](https://endpts.com/wp-content/uploads/2021/06/Joe-Jimenez-Mark-Fishman-Aditum-Bio-tile-scaled.jpg)
Aditum Bio co-founders Joe Jimenez (L) and Mark Fishman
Joe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis
Former Novartis CEO Joe Jimenez and research leader Mark Fishman are fundraising again for their life sciences firm Aditum Bio, which in-licenses translational-stage drugs and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.